Zosuquidar
- Generic Name
- Zosuquidar
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31F2N3O2
- CAS Number
- 167354-41-8
- Unique Ingredient Identifier
- AB5K82X98Y
- Background
Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
- Indication
Investigated for use/treatment in leukemia (myeloid) and myelodysplastic syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
Complex IIa formation and ABC transporters determine sensitivity of OSCC to Smac mimetics
Head and neck squamous cell carcinoma: risk factors, molecular alterations, immunology, and peptide vaccines.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath